Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate a new combination of chemotherapy drugs for
CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an
intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill).
The purpose of this study is to see if giving the chemotherapy pill lenalidomide after
treatment with bendamustine and rituximab is able to prolong the period of time before the
cancer starts growing again and causing symptoms.